Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75 HybridImmunity Vaccination SARSCoV2 Omicron Breakthrough COVID19
By Dr. Chinta SidharthanNov 8 2022Reviewed by Aimee Molineux In a recent study published in Eurosurveillance, researchers from Israel measured the neutralizing antibody titers against the wild-type strain of severe acute respiratory syndrome coronavirus 2 and the SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.75 and BA.5 in healthcare workers fully vaccinated with three doses of the Comirnaty vaccine, who experienced breakthrough Omicron infections.
The whole genome sequence monitoring of SARS-CoV-2 positive samples in Israel detected the introduction of the BA.2.75 subvariant in the population during the dominance of the BA.5 subvariant. The first cohort comprised 14 healthcare workers who were fully vaccinated with three doses of the Pfizer/BioNTech BNT162b2 messenger ribonucleic acid vaccine and had never had SARS-CoV-2 infections. The second cohort consisted of 15 previously uninfected healthcare workers who were fully vaccinated with three doses of the Comirnaty vaccine and had subsequently had an Omicron BA.1 breakthrough infection.
Sera of individuals from the second cohort who were fully vaccinated and had breakthrough BA.1 infections exhibited similar neutralization efficiency against all sub-variants except BA.5, against which the neutralizing efficacy was significantly lower. The neutralizing efficacy of the sera from individuals of the third cohort, who had breakthrough BA.5 infections after being fully vaccinated, showed the reverse trend, with similar neutralization efficiency against all sub-variants except BA.1.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study finds no evidence of major SARS-CoV-2 spread among wild rodentsA new study published in the Emerging Infectious Diseases journal conducted a large-scale serologic survey of SARS-CoV-2 in multiple rodent species to determine the reverse transmission of SARS-Cov-2 and its establishment in wild rodents across different settings.
Weiterlesen »
Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotelThe results of this study, published in the Emerging Infectious Diseases journal, underline the enhanced transmissibility of the Omicron variants of the virus, which takes advantage of small airstreams to jump to new hosts. 'Our findings emphasize the importance of ventilation and integrity of building structure in quarantine facilities.'
Weiterlesen »
SARS-CoV-2 activates NLRP3 inflammasomeResearchers assessed the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation.
Weiterlesen »
Study shows consistent efficacy of Paxlovid regardless of age, number of vaccinations, comorbiditiesIn a recent study posted to the medRxiv* preprint server, researchers in Canada evaluated nirmatrelvir and ritonavir (Paxlovid) effectiveness against severe coronavirus disease 2019 (COVID-19) during the dominance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and Omicron sub-VOCs in Canada.
Weiterlesen »
SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis - Communications BiologySARS-CoV-2 protein expression studies in the Drosophila heart suggest a cause of COVID-19-associated cardiac pathology via interaction of virus Nsp6 with the host MGA/MAX complex disrupting glycolysis and cardiac mitochondrial function.
Weiterlesen »